



(51) International Patent Classification:

C07C 235/52 (2006.01) A61K 31/505 (2006.01)
 C07D 213/81 (2006.01) A61P 9/10 (2006.01)
 C07D 239/34 (2006.01) A61P 29/00 (2006.01)
 A61K 31/44 (2006.01)

(21) International Application Number:

PCT/GB2014/052558

(22) International Filing Date:

20 August 2014 (20.08.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1314926.5 20 August 2013 (20.08.2013) GB

(71) Applicant (for all designated States except MG): **TAKE-DA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(71) Applicant (for MG only): **TAKEDA CAMBRIDGE LIMITED** [GB/GB]; 418 Cambridge Science Park, Cambridge CB4 0PA (GB).

(72) Inventors: **BUFFHAM, William**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **CANNING, Hannah**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **DAVENPORT, Richard**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **FARNABY, William**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **MACK, Stephen**; c/o Takeda Cambridge Ltd, 418 Cam-

bridge Science Park, Cambridge CB4 0PA (GB). **PAR-MAR, Alka**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **WRIGHT, Susanne**; c/o Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB).

(74) Agent: **JONES, Nicholas Andrew**; Withers & Rogers LLP, 4 More London Riverside, London SE1 2AU (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS



(57) Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R¹, X, m, R², Y, R³, Z, n, R⁴. A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.